ABSTRACT: Synthetic compounds for controlling or creating human immunity have the potential to revolutionize disease treatment. Motivated by challenges in this arena, we report herein a strategy to target metastatic cancer cells for immune-mediated destruction by targeting the urokinase-type plasminogen activator receptor (uPAR). Urokinase-type plasminogen activator (uPA) and uPAR are overexpressed on the surfaces of a wide range of invasive cancer cells and are believed to contribute substantially to the migratory propensities of these cells. The key component of our approach is an antibodyrecruiting molecule that targets the urokinase receptor (ARM-U). This bifunctional construct is formed by selectively, covalently attaching an antibody-binding small molecule to the active site of the urokinase enzyme. We demonstrate that ARM-U is capable of directing antibodies to the surfaces of target cancer cells and mediating both antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) against multiple human cancer cell lines. We believe that the reported strategy has the potential to inform novel treatment options for a variety of deadly, invasive cancers. C ancer is currently the second leading cause of death in the United States, having claimed over half a million American lives in 2010.
C
ancer is currently the second leading cause of death in the United States, having claimed over half a million American lives in 2010. 1 In general, metastatic cancers are particularly difficult to treat and are associated with higher levels of morbidity and mortality compared to localized tumors. 2, 3 For example, while the five-year survival rate of patients with localized melanoma is >95%, this survival rate drops to 15−30% for patients whose disease has metastasized to distant locations. 1 Since American men and women have a 38−44% chance, respectively, of developing invasive cancers during their lifetimes, 1 novel strategies for treating advancedstage invasive cancers have the potential to provide profound therapeutic impact.
Tumor metastasis begins with cancer cells invading surrounding tissues. This process is frequently accelerated by cell-surface proteases, including urokinase-type plasminogen activator (uPA), 4−6 which are capable of breaking down extracellular matrix proteins and activating migration-inducing signal transduction cascades. 7, 8 uPA binds the urokinase-type plasminogen activator receptor (uPAR) on the extracellular surface of many cancer cells, including those of the breast, colon, stomach, and bladder. 9, 10 Extensive evidence suggests that the levels of uPA and uPAR expression are substantially higher on invasive, malignant cancer cells than on either healthy tissues or benign tumors. 5,9,11−14 Indeed, in clinical settings, high levels of uPA and uPAR are used as diagnostic markers for metastatic potential and poor clinical outcome in numerous malignancies. 4,5,10,15−20 For these reasons uPA and uPAR have emerged as promising therapeutic targets. 9, 21 Data has shown that inhibitors and cytotoxic fusion proteins that target the uPA−uPAR system can both reduce the invasive potential of cancer cells 22, 23 and reduce tumor volumes in animal models 24−26 without significantly damaging healthy tissue. 26 The growing field of synthetic immunology 27 aims to develop novel synthetic materials capable of modulating the human immune system. One emerging concept in this area is to use bifunctional molecules to direct normal antibody responses to attack cancer cells that are not sufficiently recognized by the immune system on its own. Indeed, pioneering work by a number of research groups has demonstrated the promise of this and related approaches in both in vitro and in vivo settings. 28−36 We report here a novel application of this strategy to direct endogenous immunological effector mechanisms to act against uPAR-expressing human cancer cells (Figure 1 ). We have designed and synthesized two small molecules that can convert uPA into catalytically inactive, bifunctional constructs (ARM-Us) that are capable of both recruiting antibodies and directing antibody-dependent immune responses against uPARexpressing cancer cells. These small molecules quantitatively inhibit uPA's enzymatic activity by covalently binding to its active site, and this covalent modification simultaneously appends either a 2,4-dinitrophenyl (DNP) moiety or a fluorescein label. The DNP antigen is of particular interest for therapeutic application because anti-DNP antibodies have been found endogenously in the plasma of most humans. 37 Here we demonstrate that ARM-U can bind with high affinity to uPAR-expressing cancer cells, recruit antibodies to these cells, and induce phagocytosis and cytotoxicity in an antibodydependent, immune-mediated fashion. The technology reported herein represents a novel strategy to target uPARexpressing cancers, which may find broad application in treating a variety of deadly malignancies.
■ RESULTS AND DISCUSSION
ARM-U Design, Synthesis, and Evaluation. With the goal of preparing ARM-U by simultaneously inactivating uPA's catalytic activity and site-specifically attaching an antibodyrecruiting hapten to the protein, we designed chloromethyl ketones 1 and 2 ( Figure 2A ). These molecules were inspired by tripeptide 4, which has been shown to covalently inhibit several serine proteases including uPA. 38−40 Analysis of a published crystal structure of uPA bound to chloromethyl ketone inhibitor 4 ( Figure 2B ) 39 suggested to us that the glutamic acid side chain of the inhibitor would remain solvent-exposed following covalent binding and would therefore serve as an ideal site to attach an antibody-recruiting motif. Thus, we prepared chloromethyl ketones 1 and 2, which incorporate ethylene glycol-derived linkers to connect either fluorescein or DNP to the chloromethyl ketone tripeptide. Methyl ketone 3 cannot covalently bind uPA because it lacks the electrophilic chloromethyl group found in 1 and 2, so 3 therefore serves as a negative control.
We initially evaluated the reaction between uPA and compound 1 (to form ARM-U Fluor ) by measuring uPAmediated hydrolysis of a known fluorogenic substrate (CbzGly-Gly-Arg-7-amino-4-methylcoumarin). 41 This analysis (Supplementary Figure S1 ) reveals a 97% reduction in uPA activity versus buffer-treated uPA, which suggests that compound 1 virtually quantitatively functionalizes uPA's active site during the 1-h, ambient-temperature incubation. We further evaluated ARM-U Fluor by SDS−PAGE with in-gel fluorescence detection 40 ( Figure 3A and Supplementary Figure S2 ). Incubating uPA with 1.5 equiv of compound 1 (lane 2) substantially increases the fluorescence intensity of the protein's band at 54 kDa. Incubating uPA with higher concentrations of 1 (up to 12 equiv) does not substantially further increase the amount of fluorescence observed in this band (Supplementary Figure S3) , which suggests that 1 attaches only to a single site on uPA.
Furthermore, treating uPA with compound 3, which cannot covalently bind the protein (6 equiv, lane 3), does not lead to 39 The inhibitor is shown in stick representation with gray Cα atoms, and the protein is depicted as a turquoise surface. observable fluorescence changes in uPA's band, which implies that a covalent bonding event is necessary for complex formation with uPA. Taken together, these data suggest that compound 1 forms a 1:1 covalent complex with uPA at the enzyme's active site and provides ARM-U Fluor as a chemically defined, homogeneous reagent. The antibody-recruiting complex ARM-U DNP was prepared analogously to ARM-U Fluor by simply replacing chloromethyl ketone 1 with compound 2.
To demonstrate that ARM-U Fluor can bind anti-fluorescein antibodies, we employed an ELISA protocol. 42 ELISA wells were coated with anti-uPA antibody, treated with ARM-U Fluor (or uPA as a negative control), treated with anti-fluorescein antibody, and analyzed with alkaline-phosphatase-conjugated secondary antibody. Data from these experiments (Supplementary Figure S6 ) indicate that anti-fluorescein antibody exhibits concentration-dependent binding to ARM-U Fluor with a K d of approximately 200 pM. These results indicate that both ends of bifunctional small molecule 1 can interact simultaneously with their respective protein targets (uPA and antibody).
We next evaluated ARM-U Fluor -mediated ternary complex formation on the surface of HT-29 human colonic adenocarcinoma cells, which have been reported to express approximately 1.4 × 10 5 molecules of uPAR per cell. 43 Incubation of HT-29 cells with ARM-U Fluor , followed by antifluorescein antibody and fluorescently labeled secondary antibody, gives rise to a concentration-dependent, saturable binding interaction ( Figure 3B ). These data indicate a K d for the ARM-U Fluor −uPAR interaction of approximately 200 pM, which is consistent with previously reported values for the uPA−uPAR interaction. 4 A bifunctional construct (L-uPA Fluor ) formed from 1 and low-molecular-weight uPA, which lacks the uPAR-binding domain, 4 shows negligible cell-binding ability under identical experimental conditions. Furthermore, pretreatment of HT-29 cells with an anti-uPAR antibody that blocks the uPA binding site completely negates the cellular binding of ARM-U Fluor (Supplementary Figure S9) . These data support that ARM-U Fluor specifically targets cells via interactions with uPAR. Furthermore, these observations are consistent with our hypothesis that modifying uPA's active site should not perturb its receptor-binding ability because uPA's receptor-binding and catalytic domains reside on opposite ends of the protein.
ARM-U Mediated Cell Killing. We next evaluated the ability of ARM-U-templated ternary complexes to induce immune-mediated responses against uPAR-expressing target cells. We first studied antibody-dependent cellular phagocytosis (ADCP) using a two-color flow cytometry protocol. 44 Here we measured ARM-U-dependent phagocytosis of both HT-29 cells and A172 human glioblastoma cells (which have been reported to express approximately 1.0 × 10 6 molecules of uPAR per cell) 43 by IFN-γ-activated U937 effector cells. 45 In this ADCP assay, target and effector cells are labeled with different fluorescent cell-membrane dyes and then incubated together with ARM-U DNP and anti-DNP antibodies. Cell mixtures are then analyzed by two-color flow cytometry, and phagocytosed cells are identified as those showing fluorescence from both target and effector cells. As previously described, these doublepositive cells represent phagocytic events rather than cell−cell aggregates. 44 As illustrated in Figure 4A , phagocytosis of A172 cells increases as a function of ARM-U DNP concentration (dark blue bars), and significant levels of phagocytosis are observed at ARM-U DNP concentrations as low as 0.1 nM. At 10 nM ARM-U DNP , the level of observed phagocytosis is similar to that observed after nonspecifically labeling the target cells with high levels of antigen (trinitrophenyl sulfonic acid incubation, Supplementary Figure S10) , which indicates the high efficiency of ARM-U-mediated phagocytosis. Equivalently high levels of phagocytosis are observed when the purified anti-DNP antibody is replaced with serum from rabbits that had been immunized against the DNP hapten (Supplementary Figure  S11) . In negative control experiments, an isotype-matched antifluorescein antibody (yellow bars), which does not bind DNP, was found not to promote phagocytosis, even at high ARM-U DNP concentrations. Furthermore, the adduct between low molecular weight uPA and compound 2 (L-uPA DNP , red bars), which cannot bind uPAR, was also unable to promote phagocytosis even in the presence of anti-DNP antibody. In analogous assays (Supplementary Figure S10) , the combination of ARM-U Fluor and anti-fluorescein antibody produces high levels of phagocytosis, underscoring the requirement for a matched antigen−antibody combination. ARM-U was also capable of mediating the phagocytic uptake of HT-29 cells (Supplementary Figure S10) , albeit at slightly lower levels than for A172 cells, likely due to the slightly lower levels uPAR expression on HT-29 cells. 43 Taken together, these data suggest that the observed phagocytosis is dependent upon ternary complexes formed between uPAR, ARM-U, and epitopematched antibody on target cell surfaces.
We next studied the ability of ARM-U to induce antibodydependent cellular cytotoxicity (ADCC). To this end, we utilized the Roche xCelligence System, which uses electrical impedance to measure the adhesion of live cells to gold electrodes in culture wells ("cell index"). Detachment of dying cells from these wells leads to a corresponding decrease in impedance through the gold electrodes, which is used to measure cell death. 46, 47 Treatment of A172 target cells with ARM-U DNP , anti-DNP antibody, and freshly isolated human peripheral blood mononuclear cells (PBMCs) leads to profound time-dependent decreases in cell index that are indicative of ADCC (Supplementary Figure S12) . Indeed, concentrations of ARM-U DNP as low as 5 nM lead to substantial levels of cellular cytotoxicity in the presence of anti-DNP antibody ( Figure 4B, dark blue bars) . Control conditions employing isotype-matched anti-green-fluorescence-protein antibody (tan bars), unmodified uPA (green bars), or omitting antibody altogether (light blue bars) indicate no decreases in cell viability. Additional control experiments conducted in the absence of PBMCs reveal no antibody-dependent cytotoxic effects (Supplementary Figures S14, S15) . Together, these data suggest that the combination of ARM-U DNP , effector cells, and anti-DNP antibody is required for cytotoxic effects. In light of the importance of ADCC in mediating the effects of monoclonal-antibody-based cancer therapeutics, 48 these data suggest a functional similarity between monoclonal antibodies and the ARM-U−antibody combination.
Discussion. Here we report a novel strategy for converting a cancer-promoting enzyme (uPA) into synthetic constructs (ARM-Us) capable of targeting cancer cells for immunemediated destruction. Since the urokinase receptor is significantly upregulated on many types of cancer cells, especially the most invasive ones, ARM-U constructs have the potential to target a wide array of clinically relevant malignancies including those of the breast, colon, pancreas, and ovaries. Indeed, uPA and uPAR expression are welldocumented markers for cancer aggressiveness and poor clinical outcome, and therapeutic-targeting strategies against these proteins have shown great promise.
The reported strategy has the potential for certain advantages versus available protein-based anticancer therapeutics. uPA is readily available and can either be isolated from human urine or produced recombinantly. 49 Furthermore, since ARM-U reagents are formed by site-specifically modifying an endogenous human protein, these constructs are expected to be less likely to produce anaphylactoid or immunological side effects versus non-native proteins or their conjugates. Indeed, the catalytic domain of uPA (low-molecular-weight urokinase, trade name Abbokinase) is already FDA-approved as a safe treatment for deep vein thrombosis and pulmonary embolism. Studies have shown that cytotoxic fusion proteins can target uPARexpressing cancer cells without significant off-target damage to healthy organs, 26 and since ARM-Us are formed ex vivo with stoichiometric amounts of compounds 1 or 2, no reactive chloromethyl ketone should remain to react with off-target proteins. We believe that selective labeling of the active site is advantageous compared to alternative bioconjugation strategies, which could disrupt uPAR binding by modifying the uPARbinding domain, initiate immune-complex formation by inducing aggregation of multiple antibody proteins, or create immunogenic neo-epitopes that could initiate adaptive immune responses to the conjugate itself. 50 Furthermore, because ARM-U-mediated cell killing involves multiple multivalent recognition events, it is expected to be highly selective for cancer cells that upregulate uPAR expression. 35 Finally, by enhancing trafficking of cancer-associated antigens through immune cells, ARM-Us have the potential to give rise to long-lasting immunity. 29 Conclusion. Exploiting endogenous immunological mechanisms to selectively attack and eliminate cancer cells represents a relatively new strategy that has led to numerous developments in recent years. These successes range from Provenge, an autologous cellular immunotherapy for prostate cancer treatment, 51 to a variety of therapeutic antibodies and antibodyfusion constructs. 52−56 Using small molecules to redirect antibody-mediated immune responses has emerged as a promising anticancer strategy. 28−36 For example, a chemicallyprogrammed antibody conjugate with anti-angiogenic properties (CVX-060), is currently under investigation in Phase Ib/II clinical trials for renal cell carcinoma. 57 The approach reported here differs from these prior strategies in that it targets uPAR, which is found on a broad variety of invasive cancer cells, and also has the potential to exploit the naturally occurring, haptendirected class of anti-DNP antibodies for cancer cell destruction. Although we focus here on targeting one cancer marker (uPAR) using a single antibody population (anti-DNP), one can envision a collection of ARM constructs that target various cancer-associated surface proteins and a range of antibody populations. Thus, this general strategy holds promise for treating a wide range of human cancers, as well as other diseases.
■ METHODS
Materials and Chemical Synthesis. Organic chemicals were purchased from Sigma−Aldrich or Advanced ChemTech. High and low molecular weight human urokinase proteins were purchased from American Research Products or Innovative Research. Antibody reagents were purchased from Invitrogen or Rockland. HT-29, A172, and U937 cells were purchased from ATCC, grown according to the supplier's instructions, and used within 6 months of resuscitation. Molecules 1−3 were synthesized using standard organic chemistry procedures and characterized by standard techniques including 1 H and 13 C NMR spectroscopy, infrared (IR) spectroscopy, and mass spectrometry. Molecules 1−3 were purified to analytical purity using preparative reverse phase HPLC.
Enzymatic Analysis. uPA (10 μM) was incubated with either compound 1 (15 μM) or buffer at ambient temperature for 1 h and then diluted to 20 nM with a solution of Cbz-Gly-Gly-Arg-7-amino-4-methylcoumarin (96 μM). Fluorescence (330 nm absorbance, 460 nm emission) was monitored at 1 min intervals. Initial rates of enzymatic hydrolysis were calculated from the increase in fluorescence signal using the first five data points.
SDS-PAGE. Compound 1 (15 μM), compound 3 (60 μM), or buffer was mixed with uPA (10 μM) or buffer at ambient temperature for 1 h. Mixtures were loaded onto a 15% Tris-HCl SDS-PAGE gel, separated by electrophoresis, and visualized first by fluorescence (Typhoon Trio Variable Mode Imager, 488 nm excitation, 532 nm emission) and then by Coomassie stain.
ELISA. The wells of a 96-well polystyrene plate were coated with rabbit IgG anti-human-uPA, treated either with ARM-U Fluor or uPA, treated with goat IgG anti-fluorescein, and treated with rabbit antigoat-IgG conjugated to alkaline phosphatase. After addition of pnitrophenyl phosphate, the rate of nitrophenol liberation was measured at 405 nm using a Synergy 2 Multimode Microplate Reader. ADCC Assay. A172 cells were seeded into the analysis chamber of the Roche xCelligence System. After 12 h, ARM-U DNP (5 or 50 nM), uPA, or buffer was added. Rabbit anti-DNP IgG (27 μg/mL), rabbit anti-green-fluorescent-protein (GFP) IgG, or buffer was also added simultaneously. Freshly isolated human peripheral blood mononuclear cells (60:1 effector:target) were then added. The xCelligence System's output is termed the "cell index" and is a function of the electrical impedance through gold electrodes on the surfaces of culture plates. All cell indices were normalized to 1.0 immediately following effector cell addition and were measured every 2 min. Normal growth is defined as that shown by target cells treated with anti-DNP antibody and effector cells, but no uPA or ARM-U. Specific cytotoxicity is calculated using the following equation: specific cytotoxicity (%) = 100 − 100(cell index)/(normal growth cell index). 
